Information  X 
Enter a valid email address

Forterra plc (FORT)

  Print      Mail a friend

Monday 06 July, 2020

Forterra plc

Director Shareholdings

RNS Number : 1642S
Forterra plc
06 July 2020
 

6 July 2020

Forterra plc

Director  Shareholdings

Forterra plc (the "Company") was notified on 3 July 2020 that on the same day Vince Niblett, an Independent Non-Executive Director of the Company, purchased 2,812 ordinary shares of 1p each ("ordinary shares") in the Company at a price of £1.7779.

Vince Niblett's total beneficial interest in the ordinary shares of the Company now stands at 9,382 ordinary shares.

The above notification is intended to satisfy the Company's obligations under Article 19 of the Market Abuse Regulations.

Enquiries

Forterra plc:

+44 (0) 1604 707 600

Ashley Thompson (Company Secretary)

 

 

 

FTI Consulting :

+44 (0) 20 3727 1340

Richard Mountain/Nick Hasell

 

Further information relating to the Company and its group can be found at www.forterraplc.co.uk .

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

James Vincent Niblett

2.

Reason for the notification

a)

Position/status

Independent Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Forterra plc

b)

LEI

5299007SD2PDQMKM5278

4.

Details of the transaction(s):

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 1p each

 

GB00BYYW3C20

b)

Nature of the transaction

 

c)

Price(s) and volume(s)

Transaction

Price(s)

Volume(s)

Purchase

£1.7779

2,812

 

d)

Aggregated information

 

Transaction

Price(s)

Volume(s)

Total

 Purchase

£1.7779

2,812

£4,999.45

 

 

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHFLFVSDLIRIII

a d v e r t i s e m e n t